An Open-label, Pilot Pharmacokinetic Study to Determine the Bioavailability, Safety, and Tolerability of a Single Dose of Oradoxel in Metastatic Prostate Cancer Patients Treated With Intravenous Docetaxel

Trial Profile

An Open-label, Pilot Pharmacokinetic Study to Determine the Bioavailability, Safety, and Tolerability of a Single Dose of Oradoxel in Metastatic Prostate Cancer Patients Treated With Intravenous Docetaxel

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Docetaxel (Primary) ; HM 30181A (Primary)
  • Indications Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Athenex
  • Most Recent Events

    • 15 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 01 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top